The trajectory of copyright's flagship drug presents a interesting case for observers in the medicinal sector. While initially a blockbuster success, generating billions, the exclusivity expiration and the subsequent entry of cheaper alternatives have drastically affected income. This poses questions about the ongoing viability of analogous drug pr